Who is sponsoring NCT00945529?

NCT00945529 is sponsored by Ellen Spurrier.

What condition does NCT00945529 study?

NCT00945529 studies Congenital Heart Defect.

What drugs are being tested in NCT00945529?

Interventions: inhaled nitric oxide (iNO).

What is the status of NCT00945529?

NCT00945529 is currently COMPLETED.

Last reviewed 2023-04-26 · How we verify

The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation

NCT00945529 Phase 2/Phase 3 COMPLETED Results posted

Pleural effusions continue to be a post-operative complication seen after Fontan operation. This study will examine the use inhaled nitric oxide (iNO) given for 54 hours after Fontan operation to improve fluid balance. The study hypothesis is that inhaled nitric oxide after Fontan operation will improve fluid balance, thus decreasing the incidence of pleural effusions and shortening hospital stay.

Details

Lead sponsor	Ellen Spurrier
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	21
Start date	2008-02
Completion	2011-12

Conditions

Congenital Heart Defect

Interventions

inhaled nitric oxide (iNO)

Primary outcomes

Length of Hospital Stay Following Fontan — until hospital discharge

Countries

United States